Blackbird Laboratories
Blackbird Labs is an independent, nonprofit research platform founded in 2023, dedicated to accelerating the development and commercialization of novel medicines and technologies. It aims to build a thriving entrepreneurial ecosystem in Baltimore by collaborating with universities and investigators to bring innovative research to life. The organization is focused on de-risking technology for commercialization, attracting investment, creating startups, and fostering public-private partnerships to impact patients facing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Blackbird Laboratories
101 W Dickman St, Suite 100, Baltimore, MD 21230
Products
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut, aiming to reduce inflammation and potentially reverse the progression of Crohn's and colitis.
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut, aiming to reduce inflammation and potentially reverse the progression of Crohn's and colitis.
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut and reduce inflammation in Crohn's and colitis, aiming to reverse disease progression.
MRNA Modulator Platform Technology
A platform that enhances or restores gene expression in specific cell types using small RNAs, targeting various diseases.
MRNA Modulator Platform Technology
A platform that enhances or restores gene expression in specific cell types using small RNAs, targeting various diseases.
MRNA Modulator Platform Technology
A platform using small RNAs to enhance or restore gene expression in specific cell types, targeting various diseases.
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut, aiming to reduce inflammation and potentially reverse the progression of Crohn's and colitis.
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut, aiming to reduce inflammation and potentially reverse the progression of Crohn's and colitis.
Gut-targeted Therapeutics for Crohn’s and Colitis
Therapeutics designed to target the gut and reduce inflammation in Crohn's and colitis, aiming to reverse disease progression.
MRNA Modulator Platform Technology
A platform that enhances or restores gene expression in specific cell types using small RNAs, targeting various diseases.
MRNA Modulator Platform Technology
A platform that enhances or restores gene expression in specific cell types using small RNAs, targeting various diseases.
MRNA Modulator Platform Technology
A platform using small RNAs to enhance or restore gene expression in specific cell types, targeting various diseases.
Services
Digital platform to inform patients about clinical trial opportunities, support navigation of complex trial options, and assist enrollment processes for patients, providers, and investigators.
Platform technology to enable cell-type-specific transgene expression to improve safety and efficacy of gene therapies and extend capabilities for new therapeutic approaches.
Discovery and advancement of small-molecule neuronal receptor modulators designed to rebalance neurocircuitry and address multiple symptom domains of schizophrenia, supported by discovery and validation workflows.
Platform development focused on RNA-based therapeutics intended to upregulate mRNA targets for therapeutic effect.
Design and development of gut-restricted oral therapeutics, including inhibitors of gut-specific enzymes, with the aim of reducing inflammation and limiting systemic exposure.
Digital platform to inform patients about clinical trial opportunities, support navigation of complex trial options, and assist enrollment processes for patients, providers, and investigators.
Platform technology to enable cell-type-specific transgene expression to improve safety and efficacy of gene therapies and extend capabilities for new therapeutic approaches.
Discovery and advancement of small-molecule neuronal receptor modulators designed to rebalance neurocircuitry and address multiple symptom domains of schizophrenia, supported by discovery and validation workflows.
Platform development focused on RNA-based therapeutics intended to upregulate mRNA targets for therapeutic effect.
Design and development of gut-restricted oral therapeutics, including inhibitors of gut-specific enzymes, with the aim of reducing inflammation and limiting systemic exposure.
Expertise Areas
- Translational research commercialization
- Early-stage venture investing and portfolio management
- Platform therapeutics development (gene therapy, mRNA, small molecules)
- Digital health and patient engagement for clinical trials
Key Technologies
- Cell-type-specific gene therapy methods
- mRNA modulation therapeutics
- Small-molecule drug discovery
- Patient-facing digital clinical trial navigation platforms
News & Updates
This episode of BioTalk with Rich Bendis is a thought-provoking conversation about the work of Blackbird Laboratories.
With backing of Ravens owner, Blackbird launches with $100M to boost Baltimore’s biotech scene.
The Stephen and Renee Bisciotti Foundation created Blackbird Laboratories to create and retain more university-based startups in the region.
Blackbird Labs, a next-generation life sciences accelerator based in Baltimore City, launches with $100 million from Ravens’ Owner Steve Bisciotti.
Blackbird Labs, a next-generation life sciences accelerator, launches with $100 million and foundational collaboration with Johns Hopkins University.
This episode of BioTalk with Rich Bendis is a thought-provoking conversation about the work of Blackbird Laboratories.
With backing of Ravens owner, Blackbird launches with $100M to boost Baltimore’s biotech scene.
The Stephen and Renee Bisciotti Foundation created Blackbird Laboratories to create and retain more university-based startups in the region.
Blackbird Labs, a next-generation life sciences accelerator based in Baltimore City, launches with $100 million from Ravens’ Owner Steve Bisciotti.
Blackbird Labs, a next-generation life sciences accelerator, launches with $100 million and foundational collaboration with Johns Hopkins University.